BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 29, 2011
View Archived Issues
Highly selective mGlu4 receptor positive allosteric modulator discovered
Read More
Interim data presented from the first-in-human trial of MABp1 in advanced tumors
Read More
Action Pharma presents data from phase II trial of AP-214
Read More
University of Cambridge and Elan launch center for research focused on neurodegenerative disorders
Read More
Phase III data support lixivaptan therapy in euvolemic hyponatremia
Read More
New inhibitor of dual specificity protein kinase TTK shows promising preclinical antitumor activity
Read More
Allergy Therapeutics announces Pollinex Quattro submissions in Germany and the U.S.
Read More
Yakult gains approval for use of Elplat in new indication in Japan
Read More
PharmaGap advances anticancer liposomal formulation preparations
Read More
New vasopressin V1A receptor antagonists disclosed by Roche
Read More
Novel tumor-specific promoters designed by Korean team
Read More
Onglyza obtains E.U. approval for saxagliptin combination therapy
Read More
Novel lysosomal Pro-X carboxypeptidase inhibitors prepared by Merck & Co.
Read More
Pharmaleads announces promising phase I results of PL-37
Read More
Roche synthesizes new Mdm2 inhibitors
Read More
Exelixis signs CRADA for cabozantinib with National Cancer Institute
Read More
Shionogi patents novel cephems with antibacterial activity
Read More
SuppreMol begins SM-101 dosing in SMILE study
Read More
FDA gives clearance for phase IIa study of AEZS-130
Read More
Micromet begins study of blinatumomab in acute lymphoblastic leukemia
Read More
FDA approves Tekmira Pharmaceuticals' TKM-Ebola IND
Read More
Immunicum gains clearance for trial of dendritic cell-based anticancer vaccine
Read More
Gilead obtains European approval for Eviplera
Read More
European Commission approves Edurant for treatment-naive adults with HIV-1
Read More
Akebia begins dosing in first-in-man phase I AKB-9778 study
Read More
DMC recommends to continue Celsion's phase III HEAT study
Read More